{"id":435504,"date":"2021-02-15T07:32:07","date_gmt":"2021-02-15T12:32:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=435504"},"modified":"2021-02-15T07:32:07","modified_gmt":"2021-02-15T12:32:07","slug":"celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/","title":{"rendered":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, Yuflyma<sup>TM<\/sup> (CT-P17)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Yuflyma\u2122 (CT-P17) is the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation; 60% of adalimumab market captured by high concentration formulation in Europe according to IQVIA <\/i><\/li>\n<li><i>Yuflyma\u2122 is approved in all intended indications for the treatment of multiple chronic inflammatory diseases<\/i><\/li>\n<li><i>Yuflyma\u2122 has 29G needle size, latex-free device, and a shelf-life up to 24 months (2-8\u2103); at room temperature Yuflyma\u2122 is stable up to 30 days<\/i><\/li>\n<\/ul>\n<p>INCHEON, South Korea&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCelltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma\u2122 (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.\n<\/p>\n<p>\nThe EC approval of Yuflyma\u2122 follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in December 2020. The marketing authorisation is based on analytical, preclinical and clinical studies, demonstrating that Yuflyma\u2122 is comparable to adalimumab, the reference product, in terms of safety, efficacy, PK\/PD and immunogenicity up to 24 weeks<sup>1<\/sup> and 1 year<sup>2<\/sup> following treatment. Based on the results of the pivotal study, a high concentration formulation of Yuflyma\u2122 has been approved for use in the European Union (EU), in patients with thirteen chronic inflammatory diseases; rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohn\u2019s disease (CD), paediatric Crohn\u2019s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).\n<\/p>\n<p>\n\u201cIn Europe, according to IQVIA data, 60% of the whole adalimumab market has been taken by high concentration formulation and over 90% of the original adalimumab market has already been replaced with a high concentration version. With high concentration, low-volume, and consequently less pain, adalimumab can improve treatment adherence at the very least. Therefore, we focused on development of a high concentration biosimilar to provide a significant alternative to the adalimumab treatment category,\u201d said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. \u201cIn terms of the administration device, we have looked to ensure improved convenience for patients as well as providers with the inclusion of needle size (29G), latex-free to reduce allergy risk, and a long storage period or shelf life at room temperature for 30 days.\u201d\n<\/p>\n<p>\nProfessor Rieke Alten, Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, Teaching Hospital of Charit\u00e9, Berlin, Germany said, \u201cOver the past two decades, anti-tumour necrosis factor (TNF) biologics have revolutionised the management of chronic immune-mediated inflammatory diseases, but some of the features needed improvement for patients to reach their therapeutic goals. As a physician, we welcome these value-added features such as high concentration and low-volume formulations to reduce injection discomfort.\u201d\n<\/p>\n<p>\nThe centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. This announcement will enable affordable access to a high concentration adalimumab biosimilar, broadening treatment alternatives for patients suffering with chronic inflammatory disease including rheumatoid arthritis, psoriasis, Crohn\u2019s disease and ulcerative colitis.\n<\/p>\n<p>\nCelltrion will take the EC Decision Reliance Procedure (ECDRP) to minimise lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications to promote patients\u2019 access to advanced therapies.\n<\/p>\n<p>\n&#8211; <b>ENDS<\/b> &#8211;\n<\/p>\n<p><b>Notes to Editors:<\/b><\/p>\n<p><b>About CT-P17 (biosimilar adalimumab) <\/b><\/p>\n<p>\nCT-P17 is the first proposed high concentration, low- volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohn\u2019s disease (CD), paediatric Crohn\u2019s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human anti\u2013tumour necrosis factor \u03b1 (anti-TNF\u03b1) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.\n<\/p>\n<p><b>About Celltrion Healthcare <\/b><\/p>\n<p>\nCelltrion Healthcare is committed to delivering innovative and affordable medications to promote patients\u2019 access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.celltrionhealthcare.com%2Fen-us&amp;esheet=52378885&amp;newsitemid=20210215005195&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.celltrionhealthcare.com%2Fen-us&amp;index=1&amp;md5=fe18a1102e7c9b32299c9ca71fe57cfc\">https:\/\/www.celltrionhealthcare.com\/en-us<\/a><\/p>\n<p><span class=\"bwuline\"><b>References<\/b><\/span><\/p>\n<hr \/>\n<p><sup>1<\/sup> J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg\/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 2020<br \/>\n<br \/><sup>2<\/sup> Data on file<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210215005195\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210215005195\/en\/<\/a><\/span><\/p>\n<p>\nHolly Barber<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hbarber@hanovercomms.com\">hbarber@hanovercomms.com<br \/>\n<\/a><br \/>+44 (0) 07759 301620<\/p>\n<p>Donna Curran<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:dcurran@hanovercomms.com\">dcurran@hanovercomms.com<br \/>\n<\/a><br \/>+44 (0) 7984 550312\n<\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific South Korea<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210215005195\/en\/859086\/3\/celltrion_healthcare_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) Yuflyma\u2122 (CT-P17) is the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation; 60% of adalimumab market captured by high concentration formulation in Europe according to IQVIA Yuflyma\u2122 is approved in all intended indications for the treatment of multiple chronic inflammatory diseases Yuflyma\u2122 has 29G needle size, latex-free device, and a shelf-life up to 24 months (2-8\u2103); at room temperature Yuflyma\u2122 is stable up to 30 days INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211; Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma\u2122 (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-435504","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) Yuflyma\u2122 (CT-P17) is the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation; 60% of adalimumab market captured by high concentration formulation in Europe according to IQVIA Yuflyma\u2122 is approved in all intended indications for the treatment of multiple chronic inflammatory diseases Yuflyma\u2122 has 29G needle size, latex-free device, and a shelf-life up to 24 months (2-8\u2103); at room temperature Yuflyma\u2122 is stable up to 30 days INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211; Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma\u2122 (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for &hellip; Continue reading &quot;Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-15T12:32:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)\",\"datePublished\":\"2021-02-15T12:32:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/\"},\"wordCount\":869,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/\",\"name\":\"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-02-15T12:32:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/","og_locale":"en_US","og_type":"article","og_title":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk","og_description":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) Yuflyma\u2122 (CT-P17) is the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation; 60% of adalimumab market captured by high concentration formulation in Europe according to IQVIA Yuflyma\u2122 is approved in all intended indications for the treatment of multiple chronic inflammatory diseases Yuflyma\u2122 has 29G needle size, latex-free device, and a shelf-life up to 24 months (2-8\u2103); at room temperature Yuflyma\u2122 is stable up to 30 days INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211; Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma\u2122 (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for &hellip; Continue reading \"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-15T12:32:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)","datePublished":"2021-02-15T12:32:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/"},"wordCount":869,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/","name":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-02-15T12:32:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210215005195r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-healthcare-receives-european-commission-ec-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflymatm-ct-p17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=435504"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435504\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=435504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=435504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=435504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}